Angioedema Facial Management

Evaluation and Treatment

• The American Academy of Allergy, Asthma, and Immunology recommends identifying the etiology of angioedema to determine the specific therapeutic strategy, with treatment based on whether it is mediated by histamine or bradykinin 1
• The European Academy of Allergy and Clinical Immunology suggests evaluating airway compromise, as laryngeal angioedema represents a potentially life-threatening emergency, and identifying potential triggers such as medications (ACE inhibitors, ARB-II), trauma, emotional stress, or hormonal factors 2
• For acute attacks of hereditary angioedema (HAE), the US Hereditary Angioedema Association recommends administering a plasma-derived C1 inhibitor (1000-2000 U) intravenously, with a strength of evidence rated as high 1, 3
• The World Allergy Organization recommends icatibant (30 mg subcutaneously in the abdominal area) for acute HAE attacks, with a strength of evidence rated as moderate 2
• For short-term prophylaxis before dental or surgical procedures, the American Academy of Allergy, Asthma, and Immunology suggests administering a plasma-derived C1 inhibitor, with a strength of evidence rated as high 3
• The European Academy of Allergy and Clinical Immunology recommends androgens (danazol 2.5-10 mg/kg, maximum 600 mg/day) 5 days before until 2-3 days after the procedure, with a strength of evidence rated as moderate 4
• For long-term prophylaxis, the US Hereditary Angioedema Association recommends androgens (danazol 100 mg on alternate days up to 600 mg/day), with a strength of evidence rated as high 1, 4
• The World Allergy Organization suggests antifibrinolytic agents (tranexamic acid 30-50 mg/kg/day in 2-3 divided doses, maximum 3 g/day) for long-term prophylaxis, with a strength of evidence rated as moderate 4
• The American College of Allergy, Asthma, and Immunology recommends that the cornerstone of treatment for angioedema associated with ACE inhibitors or ARB-II is discontinuation of the offending medication, with a strength of evidence rated as high 2, 5
• The European Academy of Allergy and Clinical Immunology suggests observing patients in a controlled environment due to the risk of airway obstruction, with a strength of evidence rated as moderate 2
• The US Hereditary Angioedema Association recommends icatibant or fresh frozen plasma for acute cases, with a strength of evidence rated as high 2, 5
• The World Allergy Organization notes that antihistamines, corticosteroids, and epinephrine are generally ineffective for angioedema associated with ACE inhibitors or ARB-II, with a strength of evidence rated as moderate 2
• The American Academy of Allergy, Asthma, and Immunology recommends non-sedating H1 antihistamines as first-line treatment for histamine-mediated angioedema, with a strength of evidence rated as high 6
• The European Academy of Allergy and Clinical Immunology suggests systemic corticosteroids for moderate to severe cases, with a strength of evidence rated as moderate 6
• The American College of Allergy, Asthma, and Immunology recommends identifying and avoiding triggers, with a strength of evidence rated as high 6

Special Considerations

• The US Hereditary Angioedema Association notes that laryngeal angioedema requires close monitoring and possible advanced airway management, with a strength of evidence rated as high 3
• The World Allergy Organization suggests that antihistamines, corticosteroids, and epinephrine are not effective for hereditary angioedema, with a strength of evidence rated as moderate 1, 3
• The European Academy of Allergy and Clinical Immunology recommends analgesics, antiemetics, and aggressive hydration for abdominal attacks, with a strength of evidence rated as moderate 3